Overview

Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is to evaluate whether Dabigatran itself reduces ADP induced platelet aggregation measured by MEA as compared to Phenprocoumon after a two-week treatment with either agent.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Treatments:
Dabigatran
Phenprocoumon
Criteria
Key Inclusion Criteria:

- Patients with atrial fibrillation and an indication for oral anticoagulation
(CHA2DS2-VASc score≥ 1).

- Informed, written consent by the patient or her/his legally-authorized representative
for participation in the study.

Key Exclusion Criteria:

- Age ≤18 years

- Cardiogenic shock

- Current therapy with dabigatran

- Current, recent (2 weeks) or expected (1 week) clopidogrel therapy

- Contraindication for oral anticoagulation

- Active bleeding

- Known allergy or intolerance to the study medications: dabigatran, phenprocoumon